{
    "xml": "<topic id=\"PHP33516\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/lixisenatide\" basename=\"lixisenatide\" title=\"LIXISENATIDE\">\n<title>LIXISENATIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1252\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/lixisenatide\">Lixisenatide</xref>\n</p>\n<data name=\"vtmid\">22020311000001105</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_798882457\" title=\"Glucagon-like peptide-1 receptor agonists\">Glucagon-like peptide-1 receptor agonists</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP69318\" outputclass=\"drugAction\" rev=\"1.11\" parent=\"/drugs/lixisenatide\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69302\" outputclass=\"indicationsAndDose\" rev=\"1.18\" parent=\"/drugs/lixisenatide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus in combination with oral antidiabetic drugs (e.g. metformin, pioglitazone, or a sulfonylurea) or basal insulin, or both, when adequate glycaemic control has not been achieved with these drugs</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 10&#8239;micrograms once daily for 14 days, then increased to 20&#8239;micrograms once daily, dose to be taken within 1 hour before the first meal of the day or the evening meal.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose of concomitant sulfonylurea or insulin may need to be reduced.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69326\" outputclass=\"contraindications\" rev=\"1.6\" parent=\"/drugs/lixisenatide\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Ketoacidosis</ph>; <ph outputclass=\"contraindication\">severe gastro-intestinal disease</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69294\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/lixisenatide\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n<p>Other drugs administered orally may need to be taken at least 1 hour before or 4 hours after lixisenatide injection, or taken with a meal when lixisenatide is not administered, to minimise possible interference with absorption.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70751\" outputclass=\"sideEffects\" rev=\"1.10\" parent=\"/drugs/lixisenatide\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypoglycaemia</ph>; <ph outputclass=\"sideEffect\">injection-site reactions</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">palpitation</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Tachycardia</ph>; <ph outputclass=\"sideEffect\">urticaria</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Pancreatitis</p>\n<p>Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69340\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/lixisenatide\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Women of child-bearing age should use effective contraception.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70870\" outputclass=\"pregnancy\" parent=\"/drugs/lixisenatide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69349\" outputclass=\"breastFeeding\" parent=\"/drugs/lixisenatide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70772\" outputclass=\"renalImpairment\" parent=\"/drugs/lixisenatide\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n<p>Avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70857\" outputclass=\"patientAndCarerAdvice\" rev=\"1.10\" parent=\"/drugs/lixisenatide\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundMissedDoses\">\n<title>Missed doses</title>\n<sectiondiv>\n<p>If a dose is missed, inject within 1 hour before the next meal&#8212;do not administer <b>after</b> a meal.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Some oral medications should be taken at least 1 hour before or 4 hours after lixisenatide injection&#8212;consult product literature for details.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70639\" outputclass=\"nationalFunding\" rev=\"1.6\" parent=\"/drugs/lixisenatide\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (August 2013) that lixisenatide (<i>Lyxumia</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with oral antidiabetic drugs or basal insulin (or both), when adequate glycaemic control has not been achieved with these drugs; use is restricted to patients in whom a GLP-1 agonist is appropriate, as an alternative to an existing GLP-1 agonist (exenatide or liraglutide).</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP33516-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/lixisenatide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76076\" title=\"Solution for injection\" namespace=\"/drugs/lixisenatide/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"4\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1252\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/lixisenatide\" title=\"Lixisenatide\" count=\"1\" rel=\"link\">Lixisenatide</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76076\" namespace=\"/drugs/lixisenatide/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP33516",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/lixisenatide",
    "basename": "lixisenatide",
    "title": "LIXISENATIDE",
    "interactants": [
        {
            "id": "bnf_int_1252",
            "label": "Lixisenatide"
        }
    ],
    "vtmid": "22020311000001105",
    "drugClassification": [
        "Glucagon-like peptide-1 receptor agonists"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.",
                "html": "<p>Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Type 2 diabetes mellitus in combination with oral antidiabetic drugs (e.g. metformin, pioglitazone, or a sulfonylurea) or basal insulin, or both, when adequate glycaemic control has not been achieved with these drugs",
                        "html": "Type 2 diabetes mellitus in combination with oral antidiabetic drugs (e.g. metformin, pioglitazone, or a sulfonylurea) or basal insulin, or both, when adequate glycaemic control has not been achieved with these drugs"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 10 micrograms once daily for 14 days, then increased to 20 micrograms once daily, dose to be taken within 1 hour before the first meal of the day or the evening meal.",
                        "html": "<p>Initially 10&#8239;micrograms once daily for 14 days, then increased to 20&#8239;micrograms once daily, dose to be taken within 1 hour before the first meal of the day or the evening meal.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose of concomitant sulfonylurea or insulin may need to be reduced.",
                "html": "<p>Dose of concomitant sulfonylurea or insulin may need to be reduced.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Ketoacidosis",
                "html": "Ketoacidosis"
            },
            {
                "type": "contraindications",
                "textContent": "severe gastro-intestinal disease",
                "html": "severe gastro-intestinal disease"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).\n\nOther drugs administered orally may need to be taken at least 1 hour before or 4 hours after lixisenatide injection, or taken with a meal when lixisenatide is not administered, to minimise possible interference with absorption.",
                "html": "<p>Appendix 1 (antidiabetics).</p><p>Other drugs administered orally may need to be taken at least 1 hour before or 4 hours after lixisenatide injection, or taken with a meal when lixisenatide is not administered, to minimise possible interference with absorption.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Diarrhoea",
                        "html": "Diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypoglycaemia",
                        "html": "hypoglycaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "injection-site reactions",
                        "html": "injection-site reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "palpitation",
                        "html": "palpitation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Tachycardia",
                        "html": "Tachycardia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "urticaria",
                        "html": "urticaria",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Pancreatitis",
                "textContent": "Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).",
                "html": "<p>Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Women of child-bearing age should use effective contraception.",
                "html": "<p>Women of child-bearing age should use effective contraception.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;toxicity in animal studies.",
                "html": "<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;no information available.",
                "html": "<p>Avoid&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution if eGFR 30&#8211;50 mL/minute/1.73 m2.\n\nAvoid if eGFR less than 30 mL/minute/1.73 m2&#8212;no information available.",
                "html": "<p>Use with caution if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>Avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;no information available.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundMissedDoses": [
            {
                "type": "adviceAroundMissedDoses",
                "textContent": "If a dose is missed, inject within 1 hour before the next meal&#8212;do not administer after a meal.",
                "html": "<p>If a dose is missed, inject within 1 hour before the next meal&#8212;do not administer <b>after</b> a meal.</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Some oral medications should be taken at least 1 hour before or 4 hours after lixisenatide injection&#8212;consult product literature for details.",
                "html": "<p>Some oral medications should be taken at least 1 hour before or 4 hours after lixisenatide injection&#8212;consult product literature for details.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (August 2013) that lixisenatide (Lyxumia ) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with oral antidiabetic drugs or basal insulin (or both), when adequate glycaemic control has not been achieved with these drugs; use is restricted to patients in whom a GLP-1 agonist is appropriate, as an alternative to an existing GLP-1 agonist (exenatide or liraglutide).",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (August 2013) that lixisenatide (<i>Lyxumia</i> <tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with oral antidiabetic drugs or basal insulin (or both), when adequate glycaemic control has not been achieved with these drugs; use is restricted to patients in whom a GLP-1 agonist is appropriate, as an alternative to an existing GLP-1 agonist (exenatide or liraglutide).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76076",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1252",
                "label": "Lixisenatide",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76076",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}